{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:57:48Z","timestamp":1787241468635,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s40123-024-00984-1","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T12:02:45Z","timestamp":1718971365000},"page":"2243-2254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Ten-Year Effectiveness and Safety of Trabecular Micro-Bypass\u00a0Stent\u00a0Implantation with Cataract Surgery in Patients with Glaucoma or Ocular Hypertension"],"prefix":"10.1007","volume":"13","author":[{"given":"Tobias H.","family":"Neuhann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael T.","family":"Neuhann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana M.","family":"Hornbeak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"issue":"2","key":"984_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/tvst.4.2.1","volume":"4","author":"R Susanna Jr","year":"2015","unstructured":"Susanna R Jr, et al. Why do people (Still) go blind from glaucoma? Transl Vis Sci Technol. 2015;4(2):1.","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"984_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ophtha.2013.09.003","volume":"121","author":"M Malihi","year":"2014","unstructured":"Malihi M, et al. Long-term trends in glaucoma-related blindness in Olmsted County. Minnesota Ophthalmology. 2014;121(1):134\u201341.","journal-title":"Minnesota Ophthalmology"},{"issue":"6","key":"984_CR3","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1007\/s40123-023-00831-9","volume":"12","author":"NM Radcliffe","year":"2023","unstructured":"Radcliffe NM, Shah M, Samuelson TW. Challenging the \u201cTopical Medications-First\u201d approach to glaucoma: a treatment paradigm in evolution. Ophthalmol Ther. 2023;12(6):2823\u201339.","journal-title":"Ophthalmol Ther"},{"key":"984_CR4","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.2147\/OPTH.S439457","volume":"17","author":"S Bedrood","year":"2023","unstructured":"Bedrood S, et al. Alternatives to topical glaucoma medication for glaucoma management. Clin Ophthalmol. 2023;17:3899\u2013913.","journal-title":"Clin Ophthalmol"},{"issue":"31","key":"984_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta23310","volume":"23","author":"G Gazzard","year":"2019","unstructured":"Gazzard G, et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technol Assess. 2019;23(31):1\u2013102.","journal-title":"Health Technol Assess"},{"issue":"6","key":"984_CR6","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ogla.2021.03.012","volume":"4","author":"SA Yang","year":"2021","unstructured":"Yang SA, et al. Trends and usage patterns of minimally invasive glaucoma surgery in the United States: IRIS(R) registry analysis 2013\u20132018. Ophthalmol Glaucoma. 2021;4(6):558\u201368.","journal-title":"Ophthalmol Glaucoma"},{"key":"984_CR7","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.2147\/OPTH.S257361","volume":"14","author":"AK Ma","year":"2020","unstructured":"Ma AK, et al. GlaucoMap\u2014distribution of glaucoma surgical procedures in the United States. Clin Ophthalmol. 2020;14:2551\u201360.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"984_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40662-021-00263-1","volume":"8","author":"A Salimi","year":"2021","unstructured":"Salimi A, Watt H, Harasymowycz P. Long-term outcomes of two first-generation trabecular micro-bypass stents (iStent) with phacoemulsification in primary open-angle glaucoma: eight-year results. Eye Vis (Lond). 2021;8(1):43.","journal-title":"Eye Vis (Lond)"},{"issue":"12","key":"984_CR9","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1016\/j.jcrs.2015.06.032","volume":"41","author":"TH Neuhann","year":"2015","unstructured":"Neuhann TH. Trabecular micro-bypass stent implantation during small-incision cataract surgery for open-angle glaucoma or ocular hypertension: long-term results. J Cataract Refract Surg. 2015;41(12):2664\u201371.","journal-title":"J Cataract Refract Surg"},{"issue":"3","key":"984_CR10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jcrs.2018.10.029","volume":"45","author":"TH Neuhann","year":"2019","unstructured":"Neuhann TH, et al. Long-term effectiveness and safety of trabecular microbypass stent implantation with cataract surgery in patients with glaucoma or ocular hypertension: five-year outcomes. J Cataract Refract Surg. 2019;45(3):312\u201320.","journal-title":"J Cataract Refract Surg"},{"issue":"3","key":"984_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ophtha.2010.07.007","volume":"118","author":"TW Samuelson","year":"2011","unstructured":"Samuelson TW, et al. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology. 2011;118(3):459\u201367.","journal-title":"Ophthalmology"},{"issue":"10","key":"984_CR12","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268\u201379.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"984_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archopht.121.1.48","volume":"121","author":"MC Leske","year":"2003","unstructured":"Leske MC, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121(1):48\u201356.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"984_CR14","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/archopht.120.6.714","volume":"120","author":"MO Gordon","year":"2002","unstructured":"Gordon MO, et al. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):714\u201320 (discussion 829-30).","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"984_CR15","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/archopht.126.8.1030","volume":"126","author":"BC Chauhan","year":"2008","unstructured":"Chauhan BC, et al. Canadian Glaucoma Study: 2. Risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008;126(8):1030\u20136.","journal-title":"Arch Ophthalmol"},{"key":"984_CR16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jtos.2023.05.012","volume":"29","author":"M Kolko","year":"2023","unstructured":"Kolko M, et al. Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment. Ocul Surf. 2023;29:456\u201368.","journal-title":"Ocul Surf"},{"issue":"7","key":"984_CR17","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.ophtha.2007.10.004","volume":"115","author":"WC Stewart","year":"2008","unstructured":"Stewart WC, et al. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008;115(7):1117\u201322 (e1).","journal-title":"Ophthalmology"},{"issue":"Suppl 1","key":"984_CR18","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.survophthal.2003.12.017","volume":"49","author":"TR Walters","year":"2004","unstructured":"Walters TR, et al. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol. 2004;49(Suppl 1):S26-35.","journal-title":"Surv Ophthalmol"},{"issue":"11","key":"984_CR19","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1001\/archopht.1994.01090230060021","volume":"112","author":"DC Broadway","year":"1994","unstructured":"Broadway DC, et al. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112(11):1446\u201354.","journal-title":"Arch Ophthalmol"},{"key":"984_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1477-7525-1-75","volume":"1","author":"JP Nordmann","year":"2003","unstructured":"Nordmann JP, et al. Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes. 2003;1:75.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"984_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2011.05.033","volume":"153","author":"SE Skalicky","year":"2012","unstructured":"Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153(1):1\u20139 (e2).","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"984_CR22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/IJG.0000000000001730","volume":"30","author":"AR Patel","year":"2021","unstructured":"Patel AR, et al. Economic and clinical burden associated with intensification of glaucoma topical therapy: a US claims-based analysis. J Glaucoma. 2021;30(3):242\u201350.","journal-title":"J Glaucoma"},{"issue":"10","key":"984_CR23","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s00347-016-0332-7","volume":"113","author":"IM Lanzl","year":"2016","unstructured":"Lanzl IM, Poimenidou M, Spaeth GL. Possibilities and limitations of eye drops for glaucoma therapy. Ophthalmologe. 2016;113(10):824\u201332.","journal-title":"Ophthalmologe"},{"issue":"4","key":"984_CR24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ajo.2005.04.051","volume":"140","author":"BL Nordstrom","year":"2005","unstructured":"Nordstrom BL, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140(4):598\u2013606.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"984_CR25","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","volume":"112","author":"CM Olthoff","year":"2005","unstructured":"Olthoff CM, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112(6):953\u201361.","journal-title":"Ophthalmology"},{"issue":"4","key":"984_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ophtha.2019.10.022","volume":"127","author":"PA Newman-Casey","year":"2020","unstructured":"Newman-Casey PA, et al. The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study. Ophthalmology. 2020;127(4):477\u201383.","journal-title":"Ophthalmology"},{"issue":"5","key":"984_CR27","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.ophtha.2006.01.029","volume":"113","author":"AG Konstas","year":"2006","unstructured":"Konstas AG, et al. 24-hour intraocular pressure control with maximum medical therapy compared with surgery in patients with advanced open-angle glaucoma. Ophthalmology. 2006;113(5):761\u20135 (e1).","journal-title":"Ophthalmology"},{"key":"984_CR28","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ajo.2019.08.008","volume":"207","author":"M Muniesa","year":"2019","unstructured":"Muniesa M, Ezpeleta J, Benitez I. Fluctuations of the intraocular pressure in medically versus surgically treated glaucoma patients by a contact lens sensor. Am J Ophthalmol. 2019;207:429\u201330.","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"984_CR29","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.ophtha.2004.02.017","volume":"111","author":"K Nouri-Mahdavi","year":"2004","unstructured":"Nouri-Mahdavi K, et al. Predictive factors for glaucomatous visual field progression in the advanced glaucoma intervention study. Ophthalmology. 2004;111(9):1627\u201335.","journal-title":"Ophthalmology"},{"issue":"2","key":"984_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/00061198-200004000-00002","volume":"9","author":"S Asrani","year":"2000","unstructured":"Asrani S, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9(2):134\u201342.","journal-title":"J Glaucoma"},{"issue":"9","key":"984_CR31","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1016\/j.ophtha.2011.01.047","volume":"118","author":"DC Musch","year":"2011","unstructured":"Musch DC, et al. Intraocular pressure control and long-term visual field loss in the collaborative initial glaucoma treatment study. Ophthalmology. 2011;118(9):1766\u201373.","journal-title":"Ophthalmology"},{"issue":"2","key":"984_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ajo.2007.12.003","volume":"145","author":"J Caprioli","year":"2008","unstructured":"Caprioli J. The importance of rates in glaucoma. Am J Ophthalmol. 2008;145(2):191\u20132.","journal-title":"Am J Ophthalmol"},{"key":"984_CR33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2147\/OPTH.S152268","volume":"12","author":"LJ Katz","year":"2018","unstructured":"Katz LJ, et al. Long-term titrated IOP control with one, two, or three trabecular micro-bypass stents in open-angle glaucoma subjects on topical hypotensive medication: 42-month outcomes. Clin Ophthalmol. 2018;12:255\u201362.","journal-title":"Clin Ophthalmol"},{"key":"984_CR34","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s12325-024-02788-y","volume":"41","author":"FH Hengerer","year":"2024","unstructured":"Hengerer FH, Auffarth GU, Conrad-Hengerer I. 7-Year efficacy and safety of iStent inject trabecular micro-bypass in combined and standalone usage. Adv Ther. 2024;41:1481\u201395.","journal-title":"Adv Ther"},{"issue":"9","key":"984_CR35","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.ophtha.2012.02.050","volume":"119","author":"SL Mansberger","year":"2012","unstructured":"Mansberger SL, et al. Reduction in intraocular pressure after cataract extraction: the ocular hypertension treatment study. Ophthalmology. 2012;119(9):1826\u201331.","journal-title":"Ophthalmology"},{"issue":"10","key":"984_CR36","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/S0161-6420(02)01267-8","volume":"109","author":"DS Friedman","year":"2002","unstructured":"Friedman DS, et al. Surgical strategies for coexisting glaucoma and cataract: an evidence-based update. Ophthalmology. 2002;109(10):1902\u201313.","journal-title":"Ophthalmology"},{"issue":"1","key":"984_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/ICU.0b013e328332f562","volume":"21","author":"G Vizzeri","year":"2010","unstructured":"Vizzeri G, Weinreb RN. Cataract surgery and glaucoma. Curr Opin Ophthalmol. 2010;21(1):20\u20134.","journal-title":"Curr Opin Ophthalmol"},{"issue":"5","key":"984_CR38","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jcrs.2007.12.045","volume":"34","author":"BJ Poley","year":"2008","unstructured":"Poley BJ, Lindstrom RL, Samuelson TW. Long-term effects of phacoemulsification with intraocular lens implantation in normotensive and ocular hypertensive eyes. J Cataract Refract Surg. 2008;34(5):735\u201342.","journal-title":"J Cataract Refract Surg"},{"issue":"3","key":"984_CR39","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jcrs.2004.06.046","volume":"31","author":"N Mathalone","year":"2005","unstructured":"Mathalone N, et al. Long-term intraocular pressure control after clear corneal phacoemulsification in glaucoma patients. J Cataract Refract Surg. 2005;31(3):479\u201383.","journal-title":"J Cataract Refract Surg"},{"issue":"7","key":"984_CR40","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S0886-3350(99)00107-8","volume":"25","author":"BJ Shingleton","year":"1999","unstructured":"Shingleton BJ, et al. Long-term changes in intraocular pressure after clear corneal phacoemulsification: normal patients versus glaucoma suspect and glaucoma patients. J Cataract Refract Surg. 1999;25(7):885\u201390.","journal-title":"J Cataract Refract Surg"},{"issue":"1","key":"984_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3928\/1542-8877-19990101-09","volume":"30","author":"DD Kim","year":"1999","unstructured":"Kim DD, Doyle JW, Smith MF. Intraocular pressure reduction following phacoemulsification cataract extraction with posterior chamber lens implantation in glaucoma patients. Ophthalmic Surg Lasers. 1999;30(1):37\u201340.","journal-title":"Ophthalmic Surg Lasers"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-00984-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-024-00984-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-00984-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T09:06:58Z","timestamp":1720861618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-024-00984-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["984"],"URL":"https:\/\/doi.org\/10.1007\/s40123-024-00984-1","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"16 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tobias H. Neuhann and Raphael T. Neuhann have nothing to disclose. Dana M. Hornbeak is an employee and shareholder of Glaukos Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All visits were conducted according to the tenets of the Declaration of Helsinki and the ethical standards of the responsible committee on human research (Bayrische Landes\u00e4rztekammer M\u00fcnchen); informed consent was completed for all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}